English
简体中文
Total: £ 56.28
Published Date: 2026-03-06 | Pages: 110 | Tables: 109 | Pharma & Healthcare
The global DNA Vaccines market was valued at US$ 5751 million in 2025 and is anticipated to reach US$ 9597 million by 2032, at a CAGR of 7.7% from 2026 to 2032.
DNA vaccines are vaccines that use recombinant DNA technology, introducing plasmids or other DNA vectors encoding specific antigens of a pathogen into the host organism, where host cells transcribe and translate the antigen, thus eliciting a specific immune response. Compared to traditional inactivated or attenuated vaccines, DNA vaccines offer flexibility in design, shorter production cycles, relatively high safety, and no risk of transmission of the complete pathogen. They are particularly promising in prevention of infectious diseases, tumor immunotherapy, and rapid response to public health threats, thanks to their capability for rapid customization, large-scale production, and comparatively easier storage, making them a key focus for global biopharma companies, governments, and research institutions.
Amid growing global public health needs, frequent emergence of infectious disease variants, rising cancer incidence, and escalating antimicrobial resistance, DNA vaccines are increasingly viewed as core next-generation vaccine and immunotherapy solutions. Governments and international agencies have significantly increased funding for research targeting emerging pathogens (such as coronaviruses, malaria, dengue etc.), thereby providing continuous policy and financial support for DNA vaccine projects. At the same time, leaps in synthetic biology, gene synthesis, plasmid design and immunogenicity optimization have shortened timelines from lab validation to clinical stages, reducing failure costs. In clinical trials, multiple DNA vaccine candidates have shown positive safety profiles and immune responses (including T cell responses), boosting the confidence of markets and investors. Moreover, demand in the animal health / veterinary vaccine sector continues to accelerate, as viral and parasitic diseases exact heavy losses in livestock/aquaculture, and DNA vaccines’ advantages in cold chain and transport make them particularly appealing, making those markets important early commercial footholds. Market valuation forecasts suggest the DNA vaccine industry will grow at a roughly 6-7% compound annual growth rate over the next decade, with market size likely to double, yielding large profit potential along the entire chain—from R&D through manufacturing and distribution.
However, for DNA vaccines to become mainstream there are substantial challenges. First is immunogenicity: the strength and durability of immune responses in humans, especially relative to protein-based or viral vector vaccines, remain uncertain; some candidates in early trials have not elicited sufficiently high neutralizing antibodies or lasting T cell responses. Second, regulatory approval processes are stringent; different jurisdictions impose very cautious requirements about safety, long-term effects, gene insertion risks, etc., which may lengthen time to market and raise costs. Third, cost and production complexity are high, particularly in plasmid production, purification, delivery systems, and storage/transport (including cold or semi-cold chain) steps. High standard GMP facilities and rigorous quality control are essential; any lapse can impact stability and safety. Fourth, market education and acceptance: medical practitioners, patients, and public health bodies are still learning; uncertainty around side effects or long-term outcomes may fuel hesitancy and reduce uptake.
Downstream, preventive applications (for infectious diseases) remain the dominant demand, especially in regions with frequent outbreaks or under-served by existing vaccine supply. Post-COVID-19, prime-boost regimens, booster shots, and heterologous immunization strategies are giving DNA vaccines renewed interest as stable, rapidly producible complements. Therapeutic applications are growing fast: cancer vaccines, chronic viral infections (e.g. HIV, HBV/HCV), parasitic/fungal disease vaccines are under clinical or early stage research. In the veterinary sector, demand is robust in poultry, aquaculture, and livestock for DNA vaccines that reduce disease losses, antibiotic use, and enhance yield. Public health bodies and government purchasers increasingly focus on total life-cycle cost: transportation & storage infrastructure, dose volume, durability, breadth of immune coverage—all of which amplify the attractiveness of DNA vaccines that are stable, require fewer doses, and have broad immune responses.
This report delivers a comprehensive overview of the global DNA Vaccines market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding DNA Vaccines. The DNA Vaccines market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global DNA Vaccines market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist DNA Vaccines manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Merck
GSK
Sanofi
Zoties
Elanco
Boehringer-Ingelheim
Indian Immunologicals
Plumbline Life Sciences
Segment by Type
Recombinant Protein Vaccine
Gene-Based Vaccine
Segment by Application
Human
Animal
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for DNA Vaccines companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global DNA Vaccines Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Recombinant Protein Vaccine
1.2.3 Gene-Based Vaccine
1.3 Market by Application
1.3.1 Global DNA Vaccines Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Human
1.3.3 Animal
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global DNA Vaccines Market Perspective (2021–2032)
2.2 Global DNA Vaccines Growth Trends by Region
2.2.1 Global DNA Vaccines Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 DNA Vaccines Historic Market Size by Region (2021–2026)
2.2.3 DNA Vaccines Forecasted Market Size by Region (2027–2032)
2.3 DNA Vaccines Market Dynamics
2.3.1 DNA Vaccines Industry Trends
2.3.2 DNA Vaccines Market Drivers
2.3.3 DNA Vaccines Market Challenges
2.3.4 DNA Vaccines Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top DNA Vaccines Players by Revenue
3.1.1 Global Top DNA Vaccines Players by Revenue (2021–2026)
3.1.2 Global DNA Vaccines Revenue Market Share by Players (2021–2026)
3.2 Global Top DNA Vaccines Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by DNA Vaccines Revenue
3.4 Global DNA Vaccines Market Concentration Ratio
3.4.1 Global DNA Vaccines Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by DNA Vaccines Revenue in 2025
3.5 Global Key Players of DNA Vaccines Head Offices and Areas Served
3.6 Global Key Players of DNA Vaccines, Products and Applications
3.7 Global Key Players of DNA Vaccines, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 DNA Vaccines Breakdown Data by Type
4.1 Global DNA Vaccines Historic Market Size by Type (2021–2026)
4.2 Global DNA Vaccines Forecasted Market Size by Type (2027–2032)
5 DNA Vaccines Breakdown Data by Application
5.1 Global DNA Vaccines Historic Market Size by Application (2021–2026)
5.2 Global DNA Vaccines Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America DNA Vaccines Market Size (2021–2032)
6.2 North America DNA Vaccines Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America DNA Vaccines Market Size by Country (2021–2026)
6.4 North America DNA Vaccines Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe DNA Vaccines Market Size (2021–2032)
7.2 Europe DNA Vaccines Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe DNA Vaccines Market Size by Country (2021–2026)
7.4 Europe DNA Vaccines Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific DNA Vaccines Market Size (2021–2032)
8.2 Asia-Pacific DNA Vaccines Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific DNA Vaccines Market Size by Region (2021–2026)
8.4 Asia-Pacific DNA Vaccines Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America DNA Vaccines Market Size (2021–2032)
9.2 Latin America DNA Vaccines Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America DNA Vaccines Market Size by Country (2021–2026)
9.4 Latin America DNA Vaccines Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa DNA Vaccines Market Size (2021–2032)
10.2 Middle East & Africa DNA Vaccines Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa DNA Vaccines Market Size by Country (2021–2026)
10.4 Middle East & Africa DNA Vaccines Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck DNA Vaccines Introduction
11.1.4 Merck Revenue in DNA Vaccines Business (2021–2026)
11.1.5 Merck Recent Development
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK DNA Vaccines Introduction
11.2.4 GSK Revenue in DNA Vaccines Business (2021–2026)
11.2.5 GSK Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi DNA Vaccines Introduction
11.3.4 Sanofi Revenue in DNA Vaccines Business (2021–2026)
11.3.5 Sanofi Recent Development
11.4 Zoties
11.4.1 Zoties Company Details
11.4.2 Zoties Business Overview
11.4.3 Zoties DNA Vaccines Introduction
11.4.4 Zoties Revenue in DNA Vaccines Business (2021–2026)
11.4.5 Zoties Recent Development
11.5 Elanco
11.5.1 Elanco Company Details
11.5.2 Elanco Business Overview
11.5.3 Elanco DNA Vaccines Introduction
11.5.4 Elanco Revenue in DNA Vaccines Business (2021–2026)
11.5.5 Elanco Recent Development
11.6 Boehringer-Ingelheim
11.6.1 Boehringer-Ingelheim Company Details
11.6.2 Boehringer-Ingelheim Business Overview
11.6.3 Boehringer-Ingelheim DNA Vaccines Introduction
11.6.4 Boehringer-Ingelheim Revenue in DNA Vaccines Business (2021–2026)
11.6.5 Boehringer-Ingelheim Recent Development
11.7 Indian Immunologicals
11.7.1 Indian Immunologicals Company Details
11.7.2 Indian Immunologicals Business Overview
11.7.3 Indian Immunologicals DNA Vaccines Introduction
11.7.4 Indian Immunologicals Revenue in DNA Vaccines Business (2021–2026)
11.7.5 Indian Immunologicals Recent Development
11.8 Plumbline Life Sciences
11.8.1 Plumbline Life Sciences Company Details
11.8.2 Plumbline Life Sciences Business Overview
11.8.3 Plumbline Life Sciences DNA Vaccines Introduction
11.8.4 Plumbline Life Sciences Revenue in DNA Vaccines Business (2021–2026)
11.8.5 Plumbline Life Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global DNA Vaccines Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Recombinant Protein Vaccine
Table 3. Key Players of Gene-Based Vaccine
Table 4. Global DNA Vaccines Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global DNA Vaccines Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global DNA Vaccines Market Size by Region (US$ Million), 2021–2026
Table 7. Global DNA Vaccines Market Share by Region (2021–2026)
Table 8. Global DNA Vaccines Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global DNA Vaccines Market Share by Region (2027–2032)
Table 10. DNA Vaccines Market Trends
Table 11. DNA Vaccines Market Drivers
Table 12. DNA Vaccines Market Challenges
Table 13. DNA Vaccines Market Restraints
Table 14. Global DNA Vaccines Revenue by Players (US$ Million), 2021–2026
Table 15. Global DNA Vaccines Market Share by Players (2021–2026)
Table 16. Global Top DNA Vaccines Players by Tier (Tier 1, Tier 2, and Tier 3), based on DNA Vaccines Revenue, 2025
Table 17. Ranking of Global Top DNA Vaccines Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by DNA Vaccines Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of DNA Vaccines, Headquarters and Area Served
Table 20. Global Key Players of DNA Vaccines, Products and Applications
Table 21. Global Key Players of DNA Vaccines, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global DNA Vaccines Market Size by Type (US$ Million), 2021–2026
Table 24. Global DNA Vaccines Revenue Market Share by Type (2021–2026)
Table 25. Global DNA Vaccines Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global DNA Vaccines Revenue Market Share by Type (2027–2032)
Table 27. Global DNA Vaccines Market Size by Application (US$ Million), 2021–2026
Table 28. Global DNA Vaccines Revenue Market Share by Application (2021–2026)
Table 29. Global DNA Vaccines Forecasted Market Size by Application (US$ Million), 2027–2032
Table 30. Global DNA Vaccines Revenue Market Share by Application (2027–2032)
Table 31. North America DNA Vaccines Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America DNA Vaccines Market Size by Country (US$ Million), 2021–2026
Table 33. North America DNA Vaccines Market Size by Country (US$ Million), 2027–2032
Table 34. Europe DNA Vaccines Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe DNA Vaccines Market Size by Country (US$ Million), 2021–2026
Table 36. Europe DNA Vaccines Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific DNA Vaccines Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific DNA Vaccines Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific DNA Vaccines Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America DNA Vaccines Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America DNA Vaccines Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America DNA Vaccines Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa DNA Vaccines Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa DNA Vaccines Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa DNA Vaccines Market Size by Country (US$ Million), 2027–2032
Table 46. Merck Company Details
Table 47. Merck Business Overview
Table 48. Merck DNA Vaccines Product
Table 49. Merck Revenue in DNA Vaccines Business (US$ Million), 2021–2026
Table 50. Merck Recent Development
Table 51. GSK Company Details
Table 52. GSK Business Overview
Table 53. GSK DNA Vaccines Product
Table 54. GSK Revenue in DNA Vaccines Business (US$ Million), 2021–2026
Table 55. GSK Recent Development
Table 56. Sanofi Company Details
Table 57. Sanofi Business Overview
Table 58. Sanofi DNA Vaccines Product
Table 59. Sanofi Revenue in DNA Vaccines Business (US$ Million), 2021–2026
Table 60. Sanofi Recent Development
Table 61. Zoties Company Details
Table 62. Zoties Business Overview
Table 63. Zoties DNA Vaccines Product
Table 64. Zoties Revenue in DNA Vaccines Business (US$ Million), 2021–2026
Table 65. Zoties Recent Development
Table 66. Elanco Company Details
Table 67. Elanco Business Overview
Table 68. Elanco DNA Vaccines Product
Table 69. Elanco Revenue in DNA Vaccines Business (US$ Million), 2021–2026
Table 70. Elanco Recent Development
Table 71. Boehringer-Ingelheim Company Details
Table 72. Boehringer-Ingelheim Business Overview
Table 73. Boehringer-Ingelheim DNA Vaccines Product
Table 74. Boehringer-Ingelheim Revenue in DNA Vaccines Business (US$ Million), 2021–2026
Table 75. Boehringer-Ingelheim Recent Development
Table 76. Indian Immunologicals Company Details
Table 77. Indian Immunologicals Business Overview
Table 78. Indian Immunologicals DNA Vaccines Product
Table 79. Indian Immunologicals Revenue in DNA Vaccines Business (US$ Million), 2021–2026
Table 80. Indian Immunologicals Recent Development
Table 81. Plumbline Life Sciences Company Details
Table 82. Plumbline Life Sciences Business Overview
Table 83. Plumbline Life Sciences DNA Vaccines Product
Table 84. Plumbline Life Sciences Revenue in DNA Vaccines Business (US$ Million), 2021–2026
Table 85. Plumbline Life Sciences Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
Table 89. Authors List of This Report
List of Figures
Figure 1. DNA Vaccines Picture
Figure 2. Global DNA Vaccines Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global DNA Vaccines Market Share by Type: 2025 vs 2032
Figure 4. Recombinant Protein Vaccine Features
Figure 5. Gene-Based Vaccine Features
Figure 6. Global DNA Vaccines Market Size by Application (US$ Million), 2021–2032
Figure 7. Global DNA Vaccines Market Share by Application: 2025 vs 2032
Figure 8. Human Case Studies
Figure 9. Animal Case Studies
Figure 10. DNA Vaccines Report Years Considered
Figure 11. Global DNA Vaccines Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 12. Global DNA Vaccines Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global DNA Vaccines Market Share by Region: 2025 vs 2032
Figure 14. Global DNA Vaccines Market Share by Players in 2025
Figure 15. Global DNA Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 16. The Top 10 and 5 Players Market Share by DNA Vaccines Revenue in 2025
Figure 17. North America DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 18. North America DNA Vaccines Market Share by Country (2021–2032)
Figure 19. United States DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. Canada DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. Europe DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Europe DNA Vaccines Market Share by Country (2021–2032)
Figure 23. Germany DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. France DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. U.K. DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Italy DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Russia DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Ireland DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Asia-Pacific DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Asia-Pacific DNA Vaccines Market Share by Region (2021–2032)
Figure 31. China DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Japan DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. South Korea DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Southeast Asia DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. India DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Australia & New Zealand DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Latin America DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Latin America DNA Vaccines Market Share by Country (2021–2032)
Figure 39. Mexico DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Brazil DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Middle East & Africa DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Middle East & Africa DNA Vaccines Market Share by Country (2021–2032)
Figure 43. Israel DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Saudi Arabia DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. UAE DNA Vaccines Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Merck Revenue Growth Rate in DNA Vaccines Business (2021–2026)
Figure 47. GSK Revenue Growth Rate in DNA Vaccines Business (2021–2026)
Figure 48. Sanofi Revenue Growth Rate in DNA Vaccines Business (2021–2026)
Figure 49. Zoties Revenue Growth Rate in DNA Vaccines Business (2021–2026)
Figure 50. Elanco Revenue Growth Rate in DNA Vaccines Business (2021–2026)
Figure 51. Boehringer-Ingelheim Revenue Growth Rate in DNA Vaccines Business (2021–2026)
Figure 52. Indian Immunologicals Revenue Growth Rate in DNA Vaccines Business (2021–2026)
Figure 53. Plumbline Life Sciences Revenue Growth Rate in DNA Vaccines Business (2021–2026)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
